TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
about
Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical ImplicationsTranscription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) GeneTERT promoter mutations in thyroid cancerMutation Profile of Well-Differentiated Thyroid Cancer in AsiansThe association between the TERT rs2736100 AC genotype and reduced risk of upper tract urothelial carcinomas in a Han Chinese populationThe TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma.Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas.TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCRTERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.Clinical Characteristics and Prognostic Significance of TERT Promoter Mutations in Cancer: A Cohort Study and a Meta-Analysis.Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis.A Reduced-Intensity Conditioning Regimen for Patients with Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell TransplantationMinimally invasive follicular thyroid carcinomas: prognostic factorsThe genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients.Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas.Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.TERT Promoter Mutations in Thyroid Cancer.Understanding TERT Promoter Mutations: A Common Path to Immortality.Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance.TERT promoter hotspot mutations in breast cancer.Low frequency of TERT promoter mutations in a series of well-differentiated follicular-patterned thyroid neoplasms.Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas.Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer.Telomerase promoter mutations in human immunodeficiency virus-related conjunctiva neoplasia.Telomere Maintenance Mechanisms in Cancer.
P2860
Q26738705-581756F7-E2DE-412F-8500-936F0547F661Q26739925-ED49C1E5-6894-4D9E-87FC-590044E2BE2EQ26770808-5BD96BEF-0092-4C70-B862-3AFCFFC5FDA9Q26782322-651115FD-8A54-4BB8-B67B-D8E8FF81A8E6Q28392404-3F5E2D2B-36F5-4C02-90C8-BF5C1AEE9FF5Q33618591-60AB3B6B-257A-4185-B312-85A280D1B7E4Q33777905-AFE92359-3A09-4784-B51C-E7DFCF1F7C99Q35068013-1B0AA0D0-6B02-4B3B-B153-2E8CF0C91304Q35151119-DE71930E-455C-450F-8CC8-25D786F0BF0FQ35743608-8D60C6ED-AB32-4C76-AA21-86AE75810D4BQ35901458-BC67D4E7-BE8E-4617-B658-E680E200B11FQ36221232-BE46FDF2-E1AC-4F2E-8E71-17A5E0CBBB8EQ36782745-C0194580-FE17-4201-B7C8-59B1993B2861Q37104637-8A97BBC7-C37F-41F6-878D-E9D96AB9BD4FQ37295512-11296088-CF2F-419F-A53D-F43D74206027Q37317414-6DDE5CBD-6165-4FC3-B536-1DBB97127A7AQ38383121-BE66206E-DD42-40A5-92FA-5C576F5503E6Q38416278-A9F09B97-10F7-481F-AECD-6B6A244D799BQ38744769-2DD98117-8CF2-4A8A-B868-C296DB32AB61Q38760235-6FF99017-F38A-4E2F-91C9-5EDB24E5FE33Q40199208-130AE472-0C16-44D3-94A6-C3315C52D088Q47295202-66E53F3A-FA16-4714-87AD-03373DCD068DQ47339267-E010FBFF-9AE5-42ED-9A1D-F4E3F5082F2EQ47702648-4B3ABA91-DB10-4B7A-8253-3666D32CF5A1Q49803880-EC02ACA3-833A-4C4A-A46A-D4C36791936EQ52727349-A10A481B-260D-442A-A3BE-BDC2C9E03D21Q55122468-044409F5-7D4E-4788-89D0-E1F3B41DAA71Q55443450-E17CD5D3-5E1F-4F00-9FCA-1D51CDD0159E
P2860
TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
TERT promoter mutation as an e ...... denoma (FTA) and atypical FTA.
@en
TERT promoter mutation as an e ...... in follicular thyroid adenoma
@nl
type
label
TERT promoter mutation as an e ...... denoma (FTA) and atypical FTA.
@en
TERT promoter mutation as an e ...... in follicular thyroid adenoma
@nl
prefLabel
TERT promoter mutation as an e ...... denoma (FTA) and atypical FTA.
@en
TERT promoter mutation as an e ...... in follicular thyroid adenoma
@nl
P2093
P2860
P356
P1433
P1476
TERT promoter mutation as an e ...... denoma (FTA) and atypical FTA.
@en
P2093
Anders Höög
Catharina Larsson
Jan Zedenius
Tiantian Liu
P2860
P304
P356
10.1002/CNCR.28800
P407
P577
2014-06-04T00:00:00Z